Early preliminary data from a pilot study by Stimvia shows a noninvasive neuromodulation device known as URIS eased symptoms among participants in a pilot clinical trial and may serve as an add-on treatment for Parkinson’s disease. The device’s developer plans to release the complete data in the coming months. “We…
A group of light-responsive receptors in nerve cells called kalium channelrhodopsins can effectively turn off nerve cells in the brain, offering a potential way for scientists to dissect the mechanisms underlying brain function and what goes awry in diseases like Parkinson’s, a study found. The study, “…
Heavy coffee consumption results in lower dopamine activity in the striatum, a brain region affected in Parkinson’s disease, and does not ease motor symptoms in early diagnosed patients who have not yet been treated for the neurological disease, a study has found. However, coffee consumption before brain imaging was…
People who carry the G2019S mutation in the LRRK2 gene, the most common one associated with Parkinson’s disease, have a 10 times higher risk of developing the disease, but the risk increases to 27 times if mutations in other genes are also present. G2019S carriers developed the disease earlier, but, despite…
Scientists have harnessed the power of a protein-screening technology to identify a novel inhibitor of AAK1, an enzyme linked with Parkinson’s disease, a development that could speed the discovery of new therapies. Developing inhibitors for these specific enzymes, called kinases, has proven a difficult task due to the similar…
Lucy Therapeutics‘ (LucyTx) overall funding haul has grown to $36 million with the addition of $12.5 million more to support the company’s mitochondrial platform to develop new therapies for Parkinson’s disease. The total funding will also buttress the development of Lucy’s therapeutic pipeline for Alzheimer’s disease and…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to bemdaneprocel, a cell therapy BlueRock Therapeutics, a subsidiary of Bayer, is developing to treat Parkinson’s disease. RMAT designation is granted to therapies that have shown potential to treat serious or life-threatening…
A first-of-its kind study has identified key genes in the brain that explain why Black Americans have a lower incidence of Parkinson’s disease, but are at heightened risks for other brain disorders, including stroke and Alzheimer’s. “This landmark work enriches our understanding of the role of genetic ancestry in…
Irlab Therapeutics is preparing to start a Phase 1 clinical trial of IRL757, its oral tablet candidate to ease apathy in Parkinson’s disease and other neurological conditions. The trial, which follows its approval by the Swedish Medical Products Agency, is fully financed by a 20 million SEK (about…
A test known as the alpha-synuclein seed amplification assay, or alphaSyn-SAA, was able to measure the accumulation of alpha-synuclein protein in the blood up to 10 years before a clinical diagnosis of Parkinson’s disease, a study reported. These findings support the use of such a blood test “as a…
Get regular updates to your inbox.